search
Back to results

Expertise Asthma COPD Program With Digital Support (EXACT@home)

Primary Purpose

Asthma

Status
Recruiting
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Budesonide/Formoterol fumarate dihydrate
Sponsored by
Franciscus Gasthuis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring severe asthma, ehealth, digital home monitoring, difficult to treat asthma, treatable traits, assessment, biologics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Confirmed asthma diagnoses (≥12% and >200 ml reversibility in FEV1 or positive histamine/methacholine provocation test or FeNO ≥50) according to the asthma guidelines Diagnosed with severe, refractory asthma with eligibility for treatment with specific asthma biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab) as determined at the regional asthma MDTM according to the asthma guidelines Age ≥ 18 years. Previous prescribed asthma biologics have to be ceased ≥ 4 times the half-life of that specific biologic. The patient has be relatively stable. The onset of an asthma exacerbation and/or a respiratory infection has to be ≥ 4 weeks ago. Exclusion criteria: Primary COPD diagnosis. History of cancer: Current basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to the start of the study. Current other malignancies. Patients are eligible to participate in the study provided that curative therapy was completed at least 5 years prior to the start of the study. Inability to sufficiently understand and read the Dutch language. Being unable to engage in a remote monitoring and coaching program through the use of a smartphone. Being unable to engage in physical activity (e.g. physical disability). Current pregnancy. Current breastfeeding. A liaison with the coordinating or (principal) investigator, which could likely influence the decision to participate in this study voluntarily (in concordance with the WMO - article 5).

Sites / Locations

  • Franciscus Gasthuis & VlietlandRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention arm (EXACT@home)

Control arm (biologics)

Arm Description

These patients will first undergo the systematic assessment (=EXACT@home) of +/- 6 weeks including a systematic anamnesis, questionnaires and home monitoring with multiple digital devices (digital inhaler, activity tracker, hand-held spirometer and FeNO measuring device) and a Personal Digital Health Environment (PDHE). Based on this evaluation and the degree of asthma control a treatment will be chosen: optimization of treatable traits if present and/or biologics. The personal digital healthcare environment and digital inhaler will be used for 12 months and the activity tracker, hand-held spirometer and FeNO measuring device will be used for 12 weeks.

These patients will immediately receive a biologic after the indication is determined at the regional asthma Multi-Disciplinary Team Meeting (MDTM). These patients also have access to the Personal Digital Health Environment (PDHE) and they will also use the digital inhaler but without being able to see their own results or receiving feedback/reminders (silent). The personal digital healthcare environment and digital inhaler will be used for 12 months.

Outcomes

Primary Outcome Measures

Difference in percentage of patients treated with biologicals after 6 months of follow up
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm

Secondary Outcome Measures

Difference in percentage of patients treated with biologicals after 12 months of follow up
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm
Difference in change in asthma control over time between the intervention- and control group
Asthma Controle assessed with the Asthma Control Questionnaire (ACQ-5). This questionnaire consists of five questions about the severity of symptoms which a patient experieces. The score range per question is 0-7 (0 = never and 7 = always). The total score will be calculated by dividing the sum of all scores by the amount of questions. A higher score is associated with worse asthma control.
Difference in change in quality of life over time between the intervention- and control group
Disease specific quality of life is measured with the Asthma Quality of Life Questionnaire (mini AQLQ). The mini AQLQ consists of 15 questions, which are subdivided into 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Each question has a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall score is the mean of all 15 responses. A lower score corresponds to a better quality of life.
Difference in asthma exacerbation frequency
Asthma exacerbation frequency

Full Information

First Posted
December 20, 2022
Last Updated
April 14, 2023
Sponsor
Franciscus Gasthuis
Collaborators
Teva Pharmaceuticals USA
search

1. Study Identification

Unique Protocol Identification Number
NCT05831566
Brief Title
Expertise Asthma COPD Program With Digital Support
Acronym
EXACT@home
Official Title
Expertise Asthma COPD Program With Digital Support
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 31, 2023 (Actual)
Primary Completion Date
January 31, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Franciscus Gasthuis
Collaborators
Teva Pharmaceuticals USA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The aim EXACT@Home is to create an evidence-based health program using e.g. questionnaires, a digital health platform and multiple digital devices to further improve the assessment of patients diagnosed with severe asthma. By better charting treatable traits (e.g. poor adherence, physical inactivity, dysfunctional breathing), we expect to improve the indication for the use of biologics. One the devices that will be used is also a medicinal product: a digital inhaler, which monitors adherence and inhaler technique through its connected application and aims to improve adherence and inhaler technique with reminders and notifications. Next to this an activity tracker, hand-held spirometer and FeNO measuring device will be used. The information of the devices will be collected in a Personal Digital Healthcare Environment (PDHE). Patients diagnosed with severe asthma according to the regional asthma Multi-Disciplinary Team Meeting (MDTM) eligible for a treatment with biologics will be included. Half of the patients will immediately receive a biologic. The other half will first undergo the systematic assessment including home monitoring (=EXACT@home) and afterwards a treatment will be chosen based on this evaluation: optimization of treatable traits when present and/or biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months.
Detailed Description
Rationale: Asthma is a common multifactorial disease with chronic inflammation of the lower airways, which is in most cases adequately treated by inhalation medication. 17% of asthma patients have difficult-to-treat asthma, which is uncontrolled despite of an optimal treatment with medication due to the presence of 'treatable traits'. Examples of treatable traits are poor adherence to ICS/LABA therapy and inhaler technique, dysfunctional breathing, physical inactivity and behavior. Severe and refractory asthma is a subtype of difficult-to-treat asthma and only occurs if the asthma is uncontrolled despite optimized treatment with medication and addressing of treatable traits, which occurs in only 3.7% of all asthma patients. This group of patients is responsible for a high burden of overall disease, as well as large healthcare costs.Treatment options with biologics have fundamentally changed the care for patients with severe asthma by giving a relevant improvement in asthma control, the number of asthma exacerbations and quality of life. On the other hand, these drugs are also very expensive and must be given for the correct indication. The Centre of Excellence for severe Asthma, Franciscus Gasthuis & Vlietland, Rotterdam organizes a weekly Multi-Disciplinary Team Meeting (MDTM) for hospitals in the South-West of the Netherlands to discuss their patients with problematic asthma and to start a treatment with biologics approved for severe asthma (in this document further called biologics). Despite maximal efforts of all stakeholders, the complete overview of a patient and the treatable traits is often hampered by the complexity and heterogeneity of severe asthma. The aim of the EXACT@Home (Expertise Asthma COPD program with digital support) study is to further improve the assessment of treatable traits using ehealth before considering treatment with biologics. Objectives: Primary objective: To investigate if the EXACT@home program results in a reduced percentage of patients treated with biologics by means of systematically targeting treatable traits measured after 6 months of follow up. Secondary objectives: To determine whether the use of EXACT@home results in a reduced percentage of patients treated with biologicals after 11-12 months. Next to this it will be investigated if EXACT@home has an influence on quality of life, asthma control, dyspnea perception, lung function, exacerbation frequency, prednisolone use, direct healthcare consumption, self-management skills, patient satisfaction, adherence to ICS/LABA therapy and inhaler technique, physical activity, sleep and vital parameters. Next to this, breath pattern analysis will be performed with the electronic nose (eNose). Moreover, the safety of the Digital inhaler (BF-Digihaler-DS from Teva) and eNose (Spironose from Breathomix) and the course of the treatment in each patient will also be investigated. Study design: Open-label, randomized controlled trial with a superiority design. Study population: Patients aged ≥ 18 years, in which the diagnosis severe and refractory asthma and eligibility for treatment with biologics was determined at the regional asthma MDTM will be asked to participate in this project. Intervention (if applicable): Patients will be randomized in 2 groups (intervention - and control group). The intervention group participates in a holistic assessment called EXACT@home consisting of a period of 6 weeks addressing diagnosis, asthma phenotype and treatable traits using e.g. questionnaires and digital devices measuring airway obstruction, eosinophilic airway inflammation, adherence to ICS/LABA therapy, inhalation technique, movement, vital parameters and sleep. The information of the devices and all other information concerning the patient will be stored in an 'Personal Digital Healthcare Environment (PDHE)'. Afterwards the collected data will be evaluated. Based on this evaluation and the degree of asthma control the type of treatment will be determined: optimization of 'treatable traits' or start of treatment with biologics. The control group will immediately start the treatment with biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months. Main study parameters/endpoints: Study parameter primary outcome: Difference between the intervention and control group in the percentage of patients treated with biologicals after 6 months of follow up. Study parameters secondary outcome: The percentage of patients treated with biologicals after 11-12 months of follow up, quality of life, asthma control, dyspnea perception, lung function, exacerbation frequency, prednisolone use, direct healthcare consumption, self-management skills, patient satisfaction, adherence to ICS/LABA therapy, inhaler technique, physical activity, slap, vital parameters, breath pattern analysis with the eNose, safety of the digital inhaler and eNose and the course of the treatment in each patient. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The possible burden of the intervention group is temporarily postponing an effective treatment with biologics in favour of in depth extensive assessment in patients with a severe disease for a short period of at least 6 weeks. On the other hand, the patient could benefit from the EXACT@home assessment possibly leading to a personalized treatment, in which a treatment with biologics might not be necessary anymore. Next to this, another possible minor burden is 1 extra visit in addition to standard care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
severe asthma, ehealth, digital home monitoring, difficult to treat asthma, treatable traits, assessment, biologics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Open-label, randomized controlled trial with a superiority design. Patients will be randomly assigned to one of two groups in parallel for the duration of the study. They will either recieve biologics directly or they will undergo an in-dept assessment to map the asthma diagnosis in more detail.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
138 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm (EXACT@home)
Arm Type
Experimental
Arm Description
These patients will first undergo the systematic assessment (=EXACT@home) of +/- 6 weeks including a systematic anamnesis, questionnaires and home monitoring with multiple digital devices (digital inhaler, activity tracker, hand-held spirometer and FeNO measuring device) and a Personal Digital Health Environment (PDHE). Based on this evaluation and the degree of asthma control a treatment will be chosen: optimization of treatable traits if present and/or biologics. The personal digital healthcare environment and digital inhaler will be used for 12 months and the activity tracker, hand-held spirometer and FeNO measuring device will be used for 12 weeks.
Arm Title
Control arm (biologics)
Arm Type
Active Comparator
Arm Description
These patients will immediately receive a biologic after the indication is determined at the regional asthma Multi-Disciplinary Team Meeting (MDTM). These patients also have access to the Personal Digital Health Environment (PDHE) and they will also use the digital inhaler but without being able to see their own results or receiving feedback/reminders (silent). The personal digital healthcare environment and digital inhaler will be used for 12 months.
Intervention Type
Drug
Intervention Name(s)
Budesonide/Formoterol fumarate dihydrate
Other Intervention Name(s)
Budesonide Formoterol (BF) Digihaler Digital System (DS)
Intervention Description
The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months. It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Primary Outcome Measure Information:
Title
Difference in percentage of patients treated with biologicals after 6 months of follow up
Description
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Difference in percentage of patients treated with biologicals after 12 months of follow up
Description
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm
Time Frame
12 months
Title
Difference in change in asthma control over time between the intervention- and control group
Description
Asthma Controle assessed with the Asthma Control Questionnaire (ACQ-5). This questionnaire consists of five questions about the severity of symptoms which a patient experieces. The score range per question is 0-7 (0 = never and 7 = always). The total score will be calculated by dividing the sum of all scores by the amount of questions. A higher score is associated with worse asthma control.
Time Frame
6-12 months
Title
Difference in change in quality of life over time between the intervention- and control group
Description
Disease specific quality of life is measured with the Asthma Quality of Life Questionnaire (mini AQLQ). The mini AQLQ consists of 15 questions, which are subdivided into 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Each question has a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall score is the mean of all 15 responses. A lower score corresponds to a better quality of life.
Time Frame
6-12 months
Title
Difference in asthma exacerbation frequency
Description
Asthma exacerbation frequency
Time Frame
6-12 months
Other Pre-specified Outcome Measures:
Title
Difference in change in spirometry and FeNO over time between the intervention - and control group.
Description
Spirometry (e.g. FEV1, FVC) and FeNO measurements
Time Frame
6-12 months
Title
Difference in direct healthcare consumption between the intervention- and control group
Description
A Health Care Resource Utilization analysis will be performed by measuring the number of hospitalizations, the duration of hospitalization, the number of unscheduled visits to a health care provider (such as visits to the emergency department, general practitioner and outpatient clinic) all related to asthma and asthma exacerbations for which prednisolone with or without antibiotics was needed. This together with the cost of asthma biologics and equipment, staff and logistics for implementation and evaluation of EXACT@home.
Time Frame
6-12 months
Title
Difference in prednisolone courses between the intervention- and control group.
Description
Number of prednisolon courses
Time Frame
6-12 months
Title
Difference in reduction in prednisolone maintenance therapy (if applicable) between the intervention and control group
Description
Reduction in prednisolon maintenace therapy between the intervention- and control group. Reduction is defined as a decrease in prednisolon maintance therapy of ≥ 5 mg.
Time Frame
6-12 months
Title
Difference in cumulative prednisolon dosage between the intervention- and control group.
Description
Cumulative prednisolon dosage. The cumulative prednisolon dosage is the total amount of prednisolon a patient recieved during the year the patient participated in the study. The is calculated with prednisolone maintance therapy and prednisolone courses.
Time Frame
6-12 months
Title
Difference in self-management between the intervention- and control group.
Description
Knowledge, skills and confidence in being able to manage one's own health or illness: Patient Activation Measure (PAM). PAM is a questionnaire that measures knowledge, skills and trust in the ability to manage health or disease. The aim of PAM is to gain insight in the ability of the patient to improve their health status. It contains 13 questions that are rated on a 5-point scale. Based on the total score patients are scored along 4 levels: from very passive, not able to take control of their disease (PAM 1) towards active patients that feel completely in control of their disease (PAM 4).
Time Frame
6-12 months
Title
Difference in dyspnea perception between the intervention- and control group.
Description
Dyspnea perception is measured with the modified Medical Research Council (mMRC) dyspnea questionnaire. The MCR is a dyspnea scale, as a measure of disability in patients with respiratory disabilities. It consists of one question about shortness of breath and six possible answers. The score range 0 to 4 (0 = no shortness of breath at all and 4 = too breathless to leave the house or breathless with dressing/undressing). A higher score is therefore associated with a high burden of disease.
Time Frame
6-12 months
Title
Difference in wellbeing between the intervention- and control group
Description
Wellbeing is measured with the Wellbeing Of Older People (WOOP) questionnaire. The WOOP is a questionnaire which captures aspects relevant to the well-being of people. It consists of 9 questions. The scoring range for each question is from 1 to 5 (1 = no problems - 5 = very serious problems). The item scores will be summed to calculated the total score, which can range from 9 to 45, with higher scores indicating higher well-being.
Time Frame
6-12 months
Title
Difference in patient satisfaction between the intervention- and control group
Description
Patient satisfaction is measured with the Patients Assessment Chronic Illness Care (PACIC) questionnaire. The PACIC questionnaire measures specific actions or qualities of care, that patients report they have experienced in the delivery system. The survey includes 20 items, each with a score from 1 to 5 (1 = none of the time - 5 = always). The overall score is the mean of all 20 scores. The 20 items can also be divided into 5 subscales of which the mean can be calculated per subscale.
Time Frame
6-12 months
Title
Measuring the change over time in physical activity in the intervention group
Description
Physical activity (e.g. steps, percentage activity type) is measured with two activity trackers: the DynaPort Movemonitor from McRoberts and the Cardiowatch from Corsano.
Time Frame
6-12 months
Title
Measuring the change over time in adherence and inhaler technique in the intervention group and the control group seperately
Description
Adherence and inhaler technique are measured with the BF-Digihaler-DS, a digital inhaler which measures the moment of inhalation and inspiratory flow. Adherence is also measured with the Test of Adherence to Inhalers (TAI) questionnaire. TAI is a questionnaire which identifies patients with low adherence, determines the degree of adherence and gives an idea of the type or pattern of non-compliance. The TAI-10 consists of 10 questions and identifies patients with poor adherence and their degree of adherence. The scoring for each question ranges from 1 to 5 (1 = worst compliance - 5 = best compliance). All items provide a total score of between 10 (minimum) and 50 (maximum). A higher score is related to better adherence.
Time Frame
6-12 months
Title
Observing sleeping patterns in the intervention group
Description
Sleep is measured with the Cardiowatch from Corsano.
Time Frame
6-12 months
Title
Observing vital parameters in the intervention group.
Description
Vital parameters consists of the heart rate, respiratory rate, temperature. These are measured with the Cardiowatch from Corsano.
Time Frame
6-12 months
Title
Measuring the differences in VOCs in exhaled breath measured with the eNose between baseline and follow-up in the intervention and in the control group separately.
Description
VOCs in exhaled breath are measured with the Electronic Nose (eNose) from Breathomics
Time Frame
6-12 months
Title
Monitoring of safety of the Digital inhaler (BF-Digihaler-DS from Teva) and eNose (Spironose from Breathomix).
Description
Safety is measured by reporting adverse (device) events.
Time Frame
6-12 months
Title
Monitoring and recording the course of treatment of each patient including the explanation behind changes in treatment (e.g. stopping treatment with biologicals).
Description
The course of the treatment is documented for each patient.
Time Frame
6-12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Confirmed asthma diagnoses (≥12% and >200 ml reversibility in FEV1 or positive histamine/methacholine provocation test or FeNO ≥50) according to the asthma guidelines Diagnosed with severe, refractory asthma with eligibility for treatment with specific asthma biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab) as determined at the regional asthma MDTM according to the asthma guidelines Age ≥ 18 years. Previous prescribed asthma biologics have to be ceased ≥ 4 times the half-life of that specific biologic. The patient has be relatively stable. The onset of an asthma exacerbation and/or a respiratory infection has to be ≥ 4 weeks ago. Exclusion criteria: Primary COPD diagnosis. History of cancer: Current basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to the start of the study. Current other malignancies. Patients are eligible to participate in the study provided that curative therapy was completed at least 5 years prior to the start of the study. Inability to sufficiently understand and read the Dutch language. Being unable to engage in a remote monitoring and coaching program through the use of a smartphone. Being unable to engage in physical activity (e.g. physical disability). Current pregnancy. Current breastfeeding. A liaison with the coordinating or (principal) investigator, which could likely influence the decision to participate in this study voluntarily (in concordance with the WMO - article 5).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
L. Bult, drs.
Phone
0031104616149
Email
l.bult@franciscus.nl
First Name & Middle Initial & Last Name or Official Title & Degree
J.C.C.M. In 't Veen, dr.
Phone
0031104616149
Email
h.intveen@franciscus.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J.C.C.M. In 't Veen, dr.
Organizational Affiliation
Franciscus Gasthuis & Vlietland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Franciscus Gasthuis & Vlietland
City
Rotterdam
State/Province
Zuid-Holland
ZIP/Postal Code
3045PM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
L. Bult
Phone
+31104616149
Email
l.bult@franciscus.nl
First Name & Middle Initial & Last Name & Degree
J.C.C.M. In 't Veen
Phone
+31104616149
Email
h.intveen@franciscus.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Expertise Asthma COPD Program With Digital Support

We'll reach out to this number within 24 hrs